Earlier in 2008, J&JPRD has got license to Isogenica’s CIS display technology, as successor in business to Centocor Research & Development, for application with the J&JPRD’s Centyrin scaffold protein platform.
With this current services deal, Isogenica has got the rights to conduct discovery work with the platform.
Isogenica CEO Kevin Matthews said they have been working hard to make CIS display an ‘industrialised’ molecular biology tool and it is great to see the progress we have made rewarded with this latest collaboration.